AbbVie Says Cariprazine Met Primary Endpoint In Phase 3 Study For Major Depressive Disorder

 Biopharmaceutical company AbbVie Inc. (ABBV) announced Friday top-line results from two Phase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating the efficacy and safety of cariprazine (Vraylar) as an adjunctive treatment for patients with major depressive disorder (MDD).